Epirubicin for adjuvant therapy in node-positive breast cancer.
D000277:Adjuvants, Pharmaceutic / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D015251:Epirubicin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005252:Fees, Pharmaceutical; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology
D000277:Adjuvants, Pharmaceutic; D000903:Antibiotics, Antineoplastic; D015251:Epirubicin